Table 2.
Migraine treatment of users included in the study
| Overall (N = 163,176) | Stress-related migraine (N = 84,740) | Non stress-related migraine (N = 78,436) | p | |
|---|---|---|---|---|
| Medical characteristics | ||||
| Acute treatment (OTC) | ||||
| Total, number (% of subjects) | 102,676 (63%) | 62,325 (74%) | 40,351 (48%) | < 0.0001 |
| Ibuprofen, number (% of reported) | 57,032 (56%) | 36,163 (58%) | 20,869 (52%) | |
| Acetaminophen, number (% of reported) | 56,704 (55%) | 36,164 (58%) | 20,540 (51%) | |
| Naproxen, number (% of reported) | 15,656 (15%) | 10,370 (17%) | 5286 (13%) | |
| Acetylsalicylic acid, number (% of reported) | 4074 (4%) | 2690 (4%) | 1384 (3%) | |
| Ketorolac, number (% of reported) | 3684 (4%) | 2538 (4%) | 1146 (3%) | |
| Acute treatment (prescription) | ||||
| Total, number (% of subjects) | 65,846 (40%) | 42,056 (50%) | 23,790 (28%) | < 0.0001 |
| Sumatriptan, number (% of reported) | 27,390 (42%) | 17,684 (42%) | 9706 (41%) | |
| Rizatriptan, number (% of reported) | 17,347 (26%) | 11,150 (27%) | 6197 (26%) | |
| Ondansetron, number (% of reported) | 5474 (8%) | 3914 (9%) | 1560 (7%) | |
| Eletriptan, number (% of reported) | 4364 (7%) | 2847 (7%) | 1517 (6%) | |
| Zolmitriptan, number (% of reported) | 4349 (7%) | 2827 (7%) | 1522 (6%) | |
| Preventive treatment | ||||
| Total, number (% of subjects) | 27,029 (16.6%) | 17,993 (21%) | 9036 (11%) | < 0.0001 |
| Topiramate, number (% of reported) | 7950 (29%) | 4980 (28%) | 2970 (33%) | |
| Erenumab, number (% of reported) | 3721 (14%) | 2489 (14%) | 1232 (14%) | |
| Botox, number (% of reported) | 2532 (9%) | 1803 (10%) | 729 (8%) | |
| Galcanezumab, number (% of reported) | 2250 (8%) | 1594 (9%) | 656 (7%) | |
| Propranolol, number (% of reported) | 1899 (7%) | 1310 (7%) | 589 (7%) | |